Nanopore Diagnostics

Oxford Nanopore Diagnostics is the clinical diagnostic subsidiary of Oxford Nanopore Technologies (LSE: ONT), established in 2022 to commercialize nanopore sequencing for regulated healthcare applications. The company develops end-to-end diagnostic solutions that leverage real-time, long-read sequencing to identify pathogens, detect structural variants in cancer, and screen for rare genetic disorders. Its flagship clinical platform, the GridIon Dx, is a CE-marked sequencer designed for use in clinical laboratories. Oxford Nanopore Diagnostics has formed strategic partnerships with industry leaders such as bioMérieux, Cepheid, and Bio-Techne to develop and distribute a menu of clinical assays, including the AmPore-TB test for tuberculosis drug resistance. By providing rapid, information-rich genomic data at the point of need, the company aims to transform precision medicine and infectious disease management.